The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Min-Soo | - |
dc.contributor.author | Ahn, Yong Min | - |
dc.contributor.author | Chung, Seockhoon | - |
dc.contributor.author | Walton, Richard | - |
dc.contributor.author | Raskin, Joel | - |
dc.contributor.author | Kim, Mun Sung | - |
dc.date.accessioned | 2021-09-06T12:27:20Z | - |
dc.date.available | 2021-09-06T12:27:20Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2012-12 | - |
dc.identifier.issn | 1738-3684 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106763 | - |
dc.description.abstract | Objective To assess the relative severity of nausea in patients from Korea with major depressive disorder (MDD) who were treated with duloxetine at low (30 mg) or high (60 mg) doses, with or without food, for the first week of an 8 week treatment. Methods Adult patients (n=249), with MDD and a 17-item Hamilton Rating Scale for Depression (HAMD(17)) score of >= 15, received open-label once daily duloxetine. At Week 0, patients were randomized to 4 groups: 30 mg with food (n=63), 60 mg with food (n=59), 30 mg without food (n=64), and 60 mg without food (n=63). At Week 1, all patients switched to duloxetine 60 mg for 7 weeks. The primary outcome measure was item 112 (nausea) of the Association for Methodology and Documentation in Psychiatry adverse event scale. Effectiveness was assessed by change in HAMD(17) total score. Results Overall, 94.4% (235/249) of patients completed Week 1 and 55.0% (137/249) of patients completed the study. For Week 1, nausea was significantly less severe for patients who received 30 mg compared with 60 mg duloxetine (p=0.003), regardless of food intake. In all groups, nausea severity was highest at Week 1 and declined throughout the study. HAMD(17) score was reduced in all groups and the most common adverse event reported was nausea (145/249; 58.2%). Conclusion To minimize nausea, Korean patients with MDD who require duloxetine treatment could be given 30 mg once daily, regardless of food, for the first week followed by 60 mg once daily for the course of therapy. Psychiatry Investig 2012;9:391-399 | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN NEUROPSYCHIATRIC ASSOC | - |
dc.subject | 60 MG | - |
dc.subject | PAROXETINE | - |
dc.subject | EFFICACY | - |
dc.subject | PLACEBO | - |
dc.subject | SAFETY | - |
dc.title | The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Min-Soo | - |
dc.identifier.doi | 10.4306/pi.2012.9.4.391 | - |
dc.identifier.scopusid | 2-s2.0-84875267121 | - |
dc.identifier.wosid | 000312519100013 | - |
dc.identifier.bibliographicCitation | PSYCHIATRY INVESTIGATION, v.9, no.4, pp.391 - 399 | - |
dc.relation.isPartOf | PSYCHIATRY INVESTIGATION | - |
dc.citation.title | PSYCHIATRY INVESTIGATION | - |
dc.citation.volume | 9 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 391 | - |
dc.citation.endPage | 399 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001741305 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | 60 MG | - |
dc.subject.keywordPlus | PAROXETINE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | Phase IV | - |
dc.subject.keywordAuthor | Major depressive disorder | - |
dc.subject.keywordAuthor | Duloxetine | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordAuthor | Nausea | - |
dc.subject.keywordAuthor | Serotonin-norepinephrine reuptake inhibitor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.